Meta AnalysisID 1819

查尔酮、黄嘌呤及其衍生物对脂肪酶抑制的效率和安全性：一项系统评价

CRD42018109366

To determine the efficacy of chalcones, xanthine and their derivatives on lipase inhibition for treating obesity.

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab

Ingredient: 1Meta-analysis: 1Links: 1

Arranging relationship network...

Record Fields

Scalar fields from the final meta_analysis record.

Meta Analysis Id: 1819
Evidence Id: 10377
Core Evidence Id: 10377
Source Meta Analysis Id: 1764
Herb2 Meta Analysis Id: HBMA001764
Crd Id: CRD42018109366
Title: Efficiency and safety of chalcones, xanthine and their derivatives on lipase inhibition: a systematic review
Review Question: To determine the efficacy of chalcones, xanthine and their derivatives on lipase inhibition for treating obesity.
Study Type Included: Original studies in all types of study design including in vitro, in vivo, in silico and clinical trials.
Condition Being Studied: Obesity is a major risk factor for many chronic diseases such as cardiovascular disease (mainly heart disease and stroke), diabetes, musculoskeletal disorders (especially osteoarthritis), some cancer diseases (including endometrium, breast, ovary, prostate, liver, gallbladder, kidney and colon) [1]. Treating obesity becomes an important task that medical professionals need to address. The main strategy for fighting obesity is to prevent energy imbalance (energy input is not higher than energy consumption). However, it is difficult to maintain this balance because many foods have high energy availability, along with low levels of physical activity. Beside behavioral modifications such as diet and doing exercises, a pharmacotherapy should be considered for obesity treatment with overweight patients who have body mass index (BMI) ≥ 30 kg/m2 or ≥ 27 kg/m2 with comorbidity [2]. Thus, the pharmaceutical industry has invested massively on the production of anti-obesity drugs. For instance, in 1999, orlistat was one of the first weight-loss drugs approved by the FDA for widespread use. This compound, which is a derivative of lipstatin extracted from Streptomyces toxytricin, acts as an effective inhibitor on pancreatic lipase. This enzyme contributes to the digestion of fats from the feed into smaller molecules leading to the intestinal fat absorption. Therefore, substances with anti-lipase activity could reduce the amount of absorbed fat and show good therapeutic responses in obese patients. [3-4]. In the continued search for effective anti-obesity agents, some classes of natural compounds that have been reported to inhibit lipase activity such as flavonoids, saponins, polyphenols, triterpenes, etc. [5]. Among them, xanthine and chalcone are two groups that are recently reported as potential candidates for lipase inhibition [3, 6-8]. Those compounds may be useful in developing a functional food for obesity and become lead compounds for the design of new anti-obesity drugs. However, there is lack of clear evidence about their effects on lipase inhibition. Therefore, in our study, we summarize all available information about xanthine and chalcone derivatives that exhibit anti-lipase ability in terms of their efficiency in all types of study design including in vitro, in vivo and clinical trial studies, and also their safety on animals and human and their clinical outcomes relating to obesity treatment with a systematic review approach. References 1. WHO. Obesity and overweight. 2018. 2. Caroline M. Apovianet al.Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2015; 100 (2): 342-362. 3. Lunagariya, N.A., et al. Inhibitors of pancreatic lipase: state of the art and clinical perspectives. EXCLI journal. 2014; 13: 897. 4. Hatano, T., et al. Flavan dimers with lipase inhibitory activity from Cassia nomame. Phytochemistry. 1997; 46(5): 893-900. 5. Garza, A.L.d.l., et al. Natural inhibitors of pancreatic lipase as new players in obesity treatment. 2011. 6. Nakai, M., et al. Inhibitory effects of oolong tea polyphenols on pancreatic lipase in vitro. Journal of Agricultural and Food Chemistry. 2005. 53(11): 4593-4598. 7. Won, S.-R., et al. Licochalcone A: a lipase inhibitor from the roots of Glycyrrhiza uralensis. Food research international. 2007; 40(8): 1046-1050. 8. Birari, R.B., et al. Antiobesity and lipid lowering effects of Glycyrrhiza chalcones: experimental and computational studies. Phytomedicine. 2011. 18(8-9): 795-801.
Participant: Inclusion criteria: + Original publication reporting the lipase inhibition including weight loss and lipidemia of individual compounds related to xanthine or chalcone groups. + No restriction made for language and study design (in vitro, in vivo or silico or clinical trial) Exclusion criteria: + Non-original studies + Publication types like: thesis, book chapters, editorials, author responses, posters, letters, conference papers, reviews, and patents. + Abstract only or studies without available full text + Unreliable extracted data + Overlapped datasets
Animal
Human Disease Modelled
Intervention: Lipase inhibition of xanthine and chalcone and their derivatives in terms of their efficiency and safety.
Comparator Control: Where there are negative (i.g. placebo) or positive control (other medications), we perform a comparison in term of their efficiency and their safety.
Main Outcome: The inhibitory efficiency of chalcone, xanthine and their derivatives on lipase activity. For in vitro studies: The half maximal inhibitory concentration (IC50), minimum inhibitory concentration (MIC) For in vivo and clinical studies: weight gain/loss, lipidemia, lethal dose 50% (LD50), lethal concentration 50% (LC50), adverse reactions.
Outcome Measure
Additional Outcome: Comparison between xanthine, chalcone derivatives and approved drugs in terms of their efficiency and safety. The side effects of xanthine and chalcones and their derivatives in treatment obesity.
Study Method: Systematic review
Keyword: Chalcone; Chalcones; Enzyme Inhibitors; Humans; Lipase; Xanthine
Contact: Nguyen Tien Huy [email protected]
Organisational Affiliation: Department of Clinical Product Development, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Japan http://www.tm.nagasaki-u.ac.jp/nekken/english/
Funding Source: This study has not received any funding.
Other Selection Criteria
Final Publication
Same Topic Review
Published Protocol
Review Type
Language: English
Country: Egypt, Greece, Japan, Jordan, Libya, United States of America, Vietnam
Review Stage: Review Ongoing
First Submission Date: 2018-09-09
Registration Date: 2018-09-28
Anticipated Start Date: 2018-08-01
Anticipated Completion Date: 2019-01-01
Title Cn: 查尔酮、黄嘌呤及其衍生物对脂肪酶抑制的效率和安全性：一项系统评价
Title En: Efficiency and safety of chalcones, xanthine and their derivatives on lipase inhibition: a systematic review
Bilingual Status: complete